Apolipoprotein B Cost-Effective for Guiding Primary Prevention Lipid-Lowering Therapy

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

MONDAY, April 13, 2026 -- Apolipoprotein B (apoB) can be used as a cost-effective marker to guide primary prevention lipid-lowering therapy (LLT) compared with low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C), according to a study published online April 8 in the Journal of the American Medical Association.

Samuel Luebbe, M.D., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues examined the relative cost-effectiveness of intensifying LLT for primary prevention based on LDL-C, non-HDL-C, and apoB goals using a computer simulation model. A cohort of 250,000 statin-eligible and atherosclerotic cardiovascular disease-free U.S. adults was constructed from 4,149 participants from the 2005 to 2016 National Health and Nutrition Examination Survey. If individuals did not achieve a treated LDL-C level <100 mg/dL, non-HDL-C level <118 mg/dL, or apoB level <78.7 mg/dL, LLT was intensified.

The researchers found that 965 quality-adjusted life-years (QALYs) would be gained with a non-HDL-C goal compared with an LDL-C goal, together with a $2.1 million reduction in costs. Overall, 1,324 QALYs would be gained with an apoB goal compared with a non-HDL-C goal, together with a $40.2 million increase in costs, for an incremental cost-effectiveness ratio of $30,300 per QALY gained. An apoB goal was optimal in 65 percent of probabilistic analyses and a non-HDL-C goal was optimal in 25 percent at a willingness-to-pay threshold of $120,000 per QALY gained.

"We found that apoB testing to intensify cholesterol-lowering medication would prevent more heart attacks and strokes than current practice, and that these health benefits were achieved at a cost that represents good value for U.S. health care payers," lead author Ciaran Kohli-Lynch, Ph.D., also from the Feinberg School of Medicine, said in a statement.

One author disclosed ties to 3M; a second author disclosed ties to Boehringer Ingelheim.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-14 02:09

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords